Skip to main content
SpringerLink
Log in
Book cover

Fluoropyrimidines in Cancer Therapy

  • Book
  • © 2003

Overview

Editors:
  1. Youcef M. Rustum

    1. Roswell Park Cancer Institute, Buffalo, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (24 chapters)

  1. Front Matter

    Pages i-xii
    Download chapter PDF

  2. Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on Its Cytotoxic Effects

    • G. J. Peters
    Pages 1-27

  3. Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines

    • Gérard Milano
    Pages 29-36

  4. Biochemical Bases of the 5-Fluorouracil—Folinic Acid Interaction and of its Limitations

    • Richard G. Moran
    Pages 37-66

  5. Molecular Mechanisms Regulating the Expression of Thymidylate Synthase

    • John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, Edward Chu
    Pages 67-82

  6. Regulation of Thymidylate Synthase Gene Expression and Drug Response

    • Bruce J. Dolnick
    Pages 83-91

  7. Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action

    • Janet A. Houghton
    Pages 93-105

  8. Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications

    • Francis Lévi
    Pages 107-128

  9. Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents

    • Alberto F. Sobrero, Ornella Belvedere
    Pages 129-138

  10. Noninvasive Studies of Fluoropyrimidines

    • Walter Wolf, Cary A. Presant, Victor Waluch
    Pages 139-152

  11. Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems

    • Shousong Cao, Gunnar Hapke, Youcef M. Rustum
    Pages 153-162

  12. Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer

    • Aimery de Gramont, Christophe Louvet
    Pages 163-173

  13. Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases

    • Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti et al.
    Pages 175-182

  14. Fluoropyrimidines in Advanced Colorectal Cancer

    • Pascal Piedbois, Marc E. Buyse
    Pages 183-190

  15. The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer

    • Charles Erlichman, Richard M. Goldberg, Daniel J. Sargent
    Pages 191-198

  16. Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer

    • Roy E. Smith, Eleftherios P. Mamounas, Norman Wolmark
    Pages 199-208

  17. Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies

    • Paulo M. Hoff, Everardo D. Saad
    Pages 209-218

  18. The Development of Oral UFT with and without Leucovorin

    • Geert H. Blijham
    Pages 219-228

  19. UFT in Elderly Patients with Colorectal Cancer

    • Albert Abad, José Luis Manzano
    Pages 229-234

  20. Clinical Trials of the Eniluracil/5-Fluorouracil Combination

    • Hedy L. Kindler, Richard L. Schilsky
    Pages 235-247
Back to top

Keywords

About this book

Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

Editors and Affiliations

  • Roswell Park Cancer Institute, Buffalo, USA

    Youcef M. Rustum

Bibliographic Information

  • Book Title: Fluoropyrimidines in Cancer Therapy

  • Editors: Youcef M. Rustum

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59259-337-8

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2003

  • Hardcover ISBN: 978-0-89603-956-8Published: 02 December 2002

  • Softcover ISBN: 978-1-61737-274-2Published: 19 November 2010

  • eBook ISBN: 978-1-59259-337-8Published: 02 December 2002

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XII, 326

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation